Contrasting Tactile Systems Technology (NASDAQ:TCMD) and Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Risk and Volatility

Delcath Systems has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Valuation and Earnings

This table compares Delcath Systems and Tactile Systems Technology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23 million	5.20	$2.70 million	$0.01	1,285.00
Tactile Systems Technology	$329.52 million	2.01	$19.09 million	$0.88	33.42

Tactile Systems Technology has higher revenue and earnings than Delcath Systems. Tactile Systems Technology is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Delcath Systems and Tactile Systems Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1	1	5	0	2.57
Tactile Systems Technology	0	2	4	1	2.86

Delcath Systems currently has a consensus price target of $22.17, indicating a potential upside of 72.50%. Tactile Systems Technology has a consensus price target of $38.60, indicating a potential upside of 31.25%. Given Delcath Systems’ higher possible upside, analysts plainly believe Delcath Systems is more favorable than Tactile Systems Technology.

Insider and Institutional Ownership

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Delcath Systems and Tactile Systems Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Tactile Systems Technology	5.91%	9.70%	7.53%

Summary

Tactile Systems Technology beats Delcath Systems on 10 of the 15 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Tactile Systems Technology

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.